Literature DB >> 21281808

Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells.

Keiki Nagaharu1, Xinhui Zhang, Toshimichi Yoshida, Daisuke Katoh, Noriko Hanamura, Yuji Kozuka, Tomoko Ogawa, Taizo Shiraishi, Kyoko Imanaka-Yoshida.   

Abstract

Tenascin C (TNC) is an extracellular matrix glycoprotein up-regulated in solid tumors. Higher TNC expression is shown in invading fronts of breast cancer, which correlates with poorer patient outcome. We examined whether TNC induces epithelial-mesenchymal transition (EMT) in breast cancer. Immunohistochemical analysis of invasive ductal carcinomas showed that TNC deposition was frequent in stroma with scattered cancer cells in peripheral margins of tumors. The addition of TNC to the medium of the MCF-7 breast cancer cells caused EMT-like change and delocalization of E-cadherin and β-catenin from cell-cell contact. Although amounts of E-cadherin and β-catenin were not changed after EMT in total lysates, they were increased in the Triton X-100-soluble fractions, indicating movement from the membrane into the cytosol. In wound healing assay, cells were scattered from wound edges and showed faster migration after TNC treatment. The EMT phenotype was correlated with SRC activation through phosphorylation at Y418 and phosphorylation of focal adhesion kinase (FAK) at Y861 and Y925 of SRC substrate sites. These phosphorylated proteins colocalized with αv integrin-positive adhesion plaques. A neutralizing antibody against αv or a SRC kinase inhibitor blocked EMT. TNC could induce EMT-like change showing loss of intercellular adhesion and enhanced migration in breast cancer cells, associated with FAK phosphorylation by SRC; this may be responsible for the observed promotion of TNC in breast cancer invasion.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281808      PMCID: PMC3069868          DOI: 10.1016/j.ajpath.2010.10.015

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  59 in total

Review 1.  Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition.

Authors:  P Savagner
Journal:  Bioessays       Date:  2001-10       Impact factor: 4.345

2.  Involvement of tenascin-C in proliferation and migration of laryngeal carcinoma cells.

Authors:  T Yoshida; E Yoshimura; H Numata; Y Sakakura; T Sakakura
Journal:  Virchows Arch       Date:  1999-11       Impact factor: 4.064

Review 3.  Biomarkers for epithelial-mesenchymal transitions.

Authors:  Michael Zeisberg; Eric G Neilson
Journal:  J Clin Invest       Date:  2009-06-01       Impact factor: 14.808

4.  Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro.

Authors:  Ming-Qing Gao; Baek Gil Kim; Suki Kang; Yoon Pyo Choi; Hangran Park; Kyu Sub Kang; Nam Hoon Cho
Journal:  J Cell Sci       Date:  2010-09-14       Impact factor: 5.285

5.  Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.

Authors:  A V Bakin; A K Tomlinson; N A Bhowmick; H L Moses; C L Arteaga
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

6.  Growth promoting signaling by tenascin-C [corrected].

Authors:  Christian Ruiz; Wentao Huang; Monika E Hegi; Katrin Lange; Marie-France Hamou; Erika Fluri; Edward J Oakeley; Ruth Chiquet-Ehrismann; Gertraud Orend
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

Review 7.  Epithelial-mesenchymal transition and cell cooperativity in metastasis.

Authors:  Takanori Tsuji; Soichiro Ibaragi; Guo-fu Hu
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

8.  Tenascin-C suppresses Rho activation.

Authors:  M B Wenk; K S Midwood; J E Schwarzbauer
Journal:  J Cell Biol       Date:  2000-08-21       Impact factor: 10.539

9.  Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor.

Authors:  C S Swindle; K T Tran; T D Johnson; P Banerjee; A M Mayes; L Griffith; A Wells
Journal:  J Cell Biol       Date:  2001-07-23       Impact factor: 10.539

10.  E-cadherin as a prognostic indicator in primary breast cancer.

Authors:  C Parker; R S Rampaul; S E Pinder; J A Bell; P M Wencyk; R W Blamey; R I Nicholson; J F Robertson
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

View more
  58 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

2.  Potentiation of tumor cell invasion by co-culture with monocytes accompanying enhanced production of matrix metalloproteinase and fibronectin.

Authors:  Go Kamoshida; Ayaka Matsuda; Risa Miura; Yuri Takashima; Arisa Katsura; Tsutomu Tsuji
Journal:  Clin Exp Metastasis       Date:  2012-09-29       Impact factor: 5.150

3.  PDGF and TGF-β promote tenascin-C expression in subepithelial myofibroblasts and contribute to intestinal mucosal protection in mice.

Authors:  M S Islam; M Kusakabe; K Horiguchi; S Iino; T Nakamura; K Iwanaga; H Hashimoto; S Matsumoto; T Murata; M Hori; H Ozaki
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 4.  The role of FAK in tumor metabolism and therapy.

Authors:  Jianliang Zhang; Steven N Hochwald
Journal:  Pharmacol Ther       Date:  2013-12-09       Impact factor: 12.310

Review 5.  Collagen and PAPP-A in the Etiology of Postpartum Breast Cancer.

Authors:  Elizabeth Slocum; Doris Germain
Journal:  Horm Cancer       Date:  2019-10-20       Impact factor: 3.869

6.  Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade.

Authors:  Shuichi Fujita; Naoshi Shimojo; Fumio Terasaki; Kaoru Otsuka; Noriko Hosotani; Yuka Kohda; Takao Tanaka; Tomohiro Nishioka; Toshimichi Yoshida; Michiaki Hiroe; Yasushi Kitaura; Nobukazu Ishizaka; Kyoko Imanaka-Yoshida
Journal:  Heart Vessels       Date:  2013-01-01       Impact factor: 2.037

7.  Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.

Authors:  Zuhal Hamurcu; Nesrin Delibaşı; Seda Geçene; Elif Funda Şener; Hamiyet Dönmez-Altuntaş; Yusuf Özkul; Halit Canatan; Bulent Ozpolat
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-29       Impact factor: 4.553

8.  Histone demethylase RBP2 is critical for breast cancer progression and metastasis.

Authors:  Jian Cao; Zongzhi Liu; William K C Cheung; Minghui Zhao; Sophia Y Chen; Siew Wee Chan; Carmen J Booth; Don X Nguyen; Qin Yan
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

9.  Tenascin C and its modulatory role in tumor progression in systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  Cytotechnology       Date:  2013-03-10       Impact factor: 2.058

10.  Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.

Authors:  Shuli Xia; Bachchu Lal; Brian Tung; Shervin Wang; C Rory Goodwin; John Laterra
Journal:  Neuro Oncol       Date:  2015-08-27       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.